{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:16:58Z","timestamp":1790835418500,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neurochemistry"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Amyotrophic Lateral Sclerosis (<jats:styled-content style=\"fixed-case\">ALS<\/jats:styled-content>) is a neurodegenerative disorder that results from motor neuron damage. Cannabinoids have been proposed as treatments for <jats:styled-content style=\"fixed-case\">ALS<\/jats:styled-content> because of their anti\u2010excitotoxicity, anti\u2010oxidant and anti\u2010inflammatory effects. Preclinical studies in mice models of <jats:styled-content style=\"fixed-case\">ALS<\/jats:styled-content> have been published using a range of cannabinoid formulations and doses. To date, there has been no rigorous evaluation of these trials to assess a potential cannabinoid treatment effect. This review and meta\u2010analysis was undertaken to provide evidence for or against a treatment effect of cannabinoids in murine <jats:styled-content style=\"fixed-case\">ALS<\/jats:styled-content> models. Evidence of a treatment effect in mice may provide motivation for trials in human <jats:styled-content style=\"fixed-case\">ALS<\/jats:styled-content>. We identified a total of 10 studies; nine studies using cannabinoid treatment in transgenic <jats:styled-content style=\"fixed-case\">SOD<\/jats:styled-content>1\u2010G93A <jats:styled-content style=\"fixed-case\">ALS<\/jats:styled-content>\u2010model mice and one study in <jats:styled-content style=\"fixed-case\">TDP<\/jats:styled-content>\u201043 transgenic mice. Eight of the nine studies that used <jats:styled-content style=\"fixed-case\">SOD<\/jats:styled-content>1\u2010G93A mice expressed similarly high copy numbers of the transgene while one study used a low\u2010copy number line. Outcomes evaluated were survival time and disease progression. The latter was measured by motor function and bodyweight decline. Meta\u2010analysis of the mean difference in survival time across the seven studies showed an increase in survival of 3.84\u00a0days (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 0.35\u20137.32\u00a0days; <jats:italic>p\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.031) for cannabinoid treated compared to control <jats:styled-content style=\"fixed-case\">SOD<\/jats:styled-content>1\u2010G93A mice. It was not possible to conduct meta\u2010analyses for motor function decline or weight loss. However, eight of nine studies reported significant improvements in measures of motor function decline and one reported non\u2010significant improvements. Weight loss was significantly attenuated in four of five studies reporting this measure while the other study reported a non\u2010significant attenuation. This review provides some evidence for the efficacy of cannabinoids in prolonging survival time in an <jats:styled-content style=\"fixed-case\">ALS<\/jats:styled-content> mouse model. A delay in disease progression is also suggested following cannabinoid treatment though it was not possible to consolidate the results from reviewed studies. However, studies have moderate to high risk of bias and are highly heterogeneous. Although this review provides some evidence to support the conduct of a cannabinoid trial in human <jats:styled-content style=\"fixed-case\">ALS<\/jats:styled-content>, more standardized studies on specific cannabinoids are necessary before supporting therapeutic potential of cannabinoids in treating patients with <jats:styled-content style=\"fixed-case\">ALS<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Open science badges<\/jats:title><jats:p><jats:inline-graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"graphic\/jnc14639-gra-1001.png\" xlink:title=\"image\"\/><\/jats:p><jats:p>This article has received a badge for *Preregistration* because the study was pre\u2010registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=89274\">https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=89274<\/jats:ext-link>. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/cos.io\/our-services\/open-science-badges\/\">https:\/\/cos.io\/our-services\/open-science-badges\/<\/jats:ext-link>.<\/jats:p><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/doi.org\/10.1111\/jnc.14651\">Read\u00a0the\u00a0Editorial\u00a0Highlight\u00a0for\u00a0this\u00a0article\u00a0on\u00a0page\u00a0168<\/jats:ext-link>.<\/jats:p><\/jats:sec><jats:sec><jats:label\/><jats:p>\n<jats:boxed-text content-type=\"graphic\" position=\"anchor\"><jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/jnc14639-fig-0005-m.png\"><jats:alt-text>image<\/jats:alt-text><\/jats:graphic><\/jats:boxed-text>\n<\/jats:p><\/jats:sec>","DOI":"10.1111\/jnc.14639","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T08:45:59Z","timestamp":1544085959000},"page":"284-297","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Effects of cannabinoids in Amyotrophic Lateral Sclerosis (<scp>ALS<\/scp>) murine models: a systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8958-3737","authenticated-orcid":false,"given":"Berzenn","family":"Urbi","sequence":"first","affiliation":[{"name":"Department of Neurology Gold Coast Hospital and Health Service Southport Qld Australia"},{"name":"School of Medicine Griffith University Southport Qld Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maame Amma","family":"Owusu","sequence":"additional","affiliation":[{"name":"Office for Research Governance and Development Gold Coast Hospital and Health Service Southport Qld Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Hughes","sequence":"additional","affiliation":[{"name":"Office for Research Governance and Development Gold Coast Hospital and Health Service Southport Qld Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Katz","sequence":"additional","affiliation":[{"name":"Department of Neurology Gold Coast Hospital and Health Service Southport Qld Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Broadley","sequence":"additional","affiliation":[{"name":"Department of Neurology Gold Coast Hospital and Health Service Southport Qld Australia"},{"name":"School of Medicine Griffith University Southport Qld Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Sabet","sequence":"additional","affiliation":[{"name":"Department of Neurology Gold Coast Hospital and Health Service Southport Qld Australia"},{"name":"School of Medicine Griffith University Southport Qld Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.007237"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125312457586"},{"key":"e_1_2_9_4_1","first-page":"1","article-title":"Can animal models of disease reliably inform human studies?: E1000245","volume":"7","author":"der Bart van Worp H.","year":"2010","journal-title":"PLoS Med."},{"key":"e_1_2_9_5_1","first-page":"481","volume-title":"Strategies to prevent motoneuron degeneration in models of Amyotrophic Lateral Sclerosis","author":"Bilsland L. G","year":"2006"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161208785740081"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.05-4743fje"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1603471"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049909110369531"},{"key":"e_1_2_9_10_1","first-page":"386","article-title":"Mechanisms of neurodegeneration in amyotrophic lateral sclerosis","volume":"54","author":"Cluskey S.","year":"2001","journal-title":"J. Clin. Path."},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12631"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14216"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.197125"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280215583568"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-43"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61156-7"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.05.025"},{"key":"e_1_2_9_18_1","unstructured":"LietnerM. MeniesS.andLutzC.(2009)Working with ALS mice: Guidelines for Preclinical testing and Colony Management. Prize4Life and eJackson Laboratory."},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050552"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12262"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.03.037"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707442"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/14660820310016813"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050551"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.07.049"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01238.x"},{"key":"e_1_2_9_27_1","first-page":"170","volume-title":"Cannabinoid receptor inverse agonists as novel therapeutic agents","author":"Seely K. A","year":"2009"},{"key":"e_1_2_9_28_1","first-page":"228","volume-title":"Targeting cannabinoid CB2 receptors as potential therapeutic agents for the treatment of Amyotrophic Lateral Sclerosis","author":"Shoemaker J","year":"2007"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2006.04346.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature20413"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/17482968.2012.687264"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.3109\/21678421.2013.778554"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/14660820510030149"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.15586\/jcbmr.2015.3"}],"container-title":["Journal of Neurochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjnc.14639","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jnc.14639","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jnc.14639","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jnc.14639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T09:01:29Z","timestamp":1692608489000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jnc.14639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1111\/jnc.14639"],"URL":"https:\/\/doi.org\/10.1111\/jnc.14639","archive":["Portico"],"relation":{},"ISSN":["0022-3042","1471-4159"],"issn-type":[{"value":"0022-3042","type":"print"},{"value":"1471-4159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,18]]},"assertion":[{"value":"2018-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}